Rapivab (peramivir) / Shionogi, BioCryst  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rapivab (peramivir) / BioCryst
NCT01146353: Pharmacokinetic Assessment of Peramivir in Hospitalized Adults Undergoing Continuous Renal Replacement Therapy

Withdrawn
N/A
0
US
Midwestern University, Northwestern University, BioCryst Pharmaceuticals
Influenza, Renal Failure
02/11
02/11
ChiCTR1800019417: Clinical Effectiveness of Peramivir in the Treatment of Severe Influenza A with Primary Pneumonia

Completed
N/A
45
 
Group A patients were given peramivir sodium chloride injection ;Group B patients received peramivir sodium chloride injection and ribonucleic acid for injection II ;Group C patients were treated with peramivir sodium chloride injection and thymopetidum for injection
Suqian People's Hospital of Nanjing Gulou Hospital Group; Suqian People's Hospital of Nanjing Gulou Hospital Group, Personal research fund
Severe Influenza A with Primary Pneumonia
 
 

Download Options